Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRDN
DateTimeSourceHeadlineSymbolCompany
19/01/202421:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRDNViridian Therapeutics Inc
18/01/202403:00Business WireViridian Therapeutics Announces Pricing of Public Offering of Shares of Common StockNASDAQ:VRDNViridian Therapeutics Inc
17/01/202421:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRDNViridian Therapeutics Inc
17/01/202421:01Business WireViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockNASDAQ:VRDNViridian Therapeutics Inc
12/01/202421:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
08/01/202413:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
08/01/202413:00Business WireViridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
04/01/202413:00Business WireViridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
18/12/202316:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRDNViridian Therapeutics Inc
18/12/202313:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
18/12/202312:00Business WireViridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
12/12/202321:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRDNViridian Therapeutics Inc
08/12/202321:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VRDNViridian Therapeutics Inc
07/12/202321:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/12/202321:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRDNViridian Therapeutics Inc
30/11/202321:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VRDNViridian Therapeutics Inc
21/11/202313:00Business WireViridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:VRDNViridian Therapeutics Inc
13/11/202322:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
13/11/202321:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRDNViridian Therapeutics Inc
13/11/202321:01Business WireViridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRDNViridian Therapeutics Inc
08/11/202313:00Business WireViridian Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
03/11/202320:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
03/11/202312:00Business WireViridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of OphthalmologyNASDAQ:VRDNViridian Therapeutics Inc
02/11/202301:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/11/202320:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/11/202320:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/11/202320:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/11/202320:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/11/202320:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
01/11/202320:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VRDN